Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 6/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 6/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24003182 | 1.00 | CYP1A2 (0.35) | CYP1A2CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL8320351 | 0.93 | CHRM2 (0.34) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL12210533 | 0.93 | CHRM2 (0.34) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL15314571 | 0.93 | CHRM2 (0.34) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL19801474 | 0.83 | — | — | |
| SCHEMBL9917275 | 0.81 | CYP1A2 (0.38) | CYP1A2 | |
| SCHEMBL14828705 | 0.81 | CYP1A2 (0.38) | CYP1A2 | |
| SCHEMBL17148636 | 0.79 | CYP1A2 (0.41) | CYP1A2CHRM5 | |
| SCHEMBL8161674 | 0.77 | CYP1A2 (0.35) | CYP1A2 | |
| SCHEMBL22267858 | 0.77 | CYP1A2 (0.39) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11040954-B1 | CXCR3 receptor agonists | RECEPTOS LLC (US) | 2021-06-22 | — | — | US | disclosed |
| US-20190345133-A1 | CXCR3 RECEPTOR AGONISTS | RECEPTOS LLC | 2019-11-14 | — | — | US | disclosed |
| EP-2069327-B1 | NEW PYRIDONE DERIVATIVES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INT (DE) | 2013-10-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040954-B1 | CXCR3 receptor agonists | CXCR3, CXCR1, CCR7 | CYP1A2 1702/4885CHRM2 162/4885CHRM4 229/4885 |
| US-20190345133-A1 | CXCR3 RECEPTOR AGONISTS | CXCR3, CXCR1, CCR7 | CYP1A2 1702/4885CHRM2 162/4885CHRM4 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.